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Development of a microfluidic lab-on-a-chip platform for breast cancer early 
diagnosis 
MicroBioMed is a selected project in the Operational Program INTERREG IV-A Euregio-Meuse-Rhine. The goal is to develop a 
network of expertise through the development of a lab-on-chip demonstrator for the immunological detection of breast cancer 
(in vitro diagnostics). 
Target antigens MUC1-based reference assay Antibodies generation 
Surface modification : micropillars  
Surface plasmon resonance 
             Imprinted polymers 
Impedance spectroscopy Surface acoustic wave 
In parallel, with the use of flow 
cytometry, an assay has been 
designed which combines two 
antibodies against MUC1 (214D4, 
unspecific, and 5E5, specific to cancer 
Mucin) in order to generate a more 
sensitive and specific detection of 
cancer cells.  
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Mucin-1 (MUC1) is a well-known and 
highly validated tumor specific antigen 
which has been chosen to evaluate the 
potential of the different new designs.  
 
The silicon micropillar array 
works as an autonomous 
capillary pump, capable of 
transporting a specific 
amount of bio-samples into 
the sensing area without 
external pumping 
requirement. 
Sensor set-up for heat-conduction 
measurements (T1 = 37.0°C) 
Patent application: WO2012/076349A1 
Reference: Kasper Eersels et al., ACS Applied Materials and Interfaces 5, 7258 – 7267 (2013).  
Bound cells block the 
thermal current:  
heat-transfer resistance 
Rth increases, T2 will 
drop 
Semi-soft PU layer  
on Al chip 
Successful Anti-MUC1 antibody coupling on gold surface 
(monitored by SPR) via mixed “COOH” and “OH”  SAM 
 
After several rounds of screenings, monoclonal 
antibodies (mAb) were identified and produced. The 
different mAbs were tested for their binding to the 
corresponding BCRAs and ELISA-based assays were 
evaluated. 
Different soluble and membrane-bound breast-cancer 
related antigens (BCRA) were used to immunize BALB/c 
mice. After sufficient titers were reached, spleens were 
removed and used for standard hybridoma technology.  
Binding of cells (PBS)  
 cell lysis (SDS)  rinsing (PBS) 
65°c – 12h 
Gold nanoparticles 
(AuNPs) on a silicon 
array are being used for 
a label-free biosensing.  
 
Tests were performed 
with anti-MUC1 
antibody (214D4): 
Impedance change measured 
at 1.6 kHz (colavent binding in 
red and non-covalent in blue) 
A surface acoustic wave chip was produced using a 
piezoelectric substrate and lithographically structured 
gold electrodes.  
 
When a probe (e.g. proteins) is being deposited, the 
change in the frequency of the acoustic waves can be 
measured  
 
Potential protein serum 
biomarkers were identified 
and subsequently validated 
by three different steps: 
mRNA expression was 
determined in benign and 
malignant breast cancer cell 
lines.  
Next, expression of candidate genes was measured on 
mRNA and protein level using a collection of fresh frozen 
breast cancer specimens and healthy breast tissues. For 
candidates confirmed as upregulated in breast cancer 
tissue, Western Blot analysis and ELISA assays were 
performed using human serum samples.  
The performance of a multi-marker-
panel was optimised using receiver 
operator characteristics (ROC) curve 
analysis.  89,5 % Specificity 
64,5 % Sensitivity 
ROC curve analysis for marker-panel   
